16,864 reports of this reaction
2.4% of all TOCILIZUMAB reports
#5 most reported adverse reaction
ARTHRALGIA is the #5 most commonly reported adverse reaction for TOCILIZUMAB, manufactured by Genentech, Inc.. There are 16,864 FDA adverse event reports linking TOCILIZUMAB to ARTHRALGIA. This represents approximately 2.4% of all 689,384 adverse event reports for this drug.
TOCILIZUMAB has an overall safety score of 85 out of 100. Patients taking TOCILIZUMAB who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is a less commonly reported adverse event for TOCILIZUMAB, but still significant enough to appear in the safety profile.
In addition to arthralgia, the following adverse reactions have been reported for TOCILIZUMAB:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 16,864 FDA reports for TOCILIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 2.4% of all adverse event reports for TOCILIZUMAB, making it a notable side effect.
If you experience arthralgia while taking TOCILIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.